IDH1 and glioma: Unfortunately, the number of samples with a known genetic tissue profile to classify patients into a glioma molecular subgroup were too low to draw any statistically valid conclusions, which is a limitation of this study, even though 4 patients with confirmed mutant IDH status were mostly classified correctly in the platelet-based predictions.